RNA sequencing and whole genome sequencing services
Open Pre-Solicitation Posted
- Solicitation number
- 75N98027Q00043
- Agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 32599 All Other Chemical Product and Preparation Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Bethesda, Maryland 20892, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health's National Cancer Institute intends to award a sole-source, firm-fixed-price purchase order to Plasmidsaurus Inc. for RNA sequencing and whole genome sequencing services, with responses due November 6, 2026. The Government cites FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements, as the basis, and the notice states that it is not a request for competitive quotations. No set-aside is used. The notice is listed under NIH's Office of Logistics and Acquisition Operations, with NAICS 32599 and PSC Q301, and is numbered 75N98027Q00020.
The requirement covers wild-type and drug-treated cell lines and samples related to CRISPR research. The primary objective is to investigate lymphoma-related translocations involving MYC, BCL6, or BCL2, examine copy number alterations, and make CNV calls for genes of interest. RNA sequencing will be performed on samples generated in the Staudt laboratory to characterize genome edits and support transcriptomic analysis. The Government justifies the single source on Plasmidsaurus's use of the latest Oxford Nanopore Technologies platform, which it describes as faster and more scalable than traditional sequencing methods and as ensuring accurate, reproducible results.
Notice text
NOTICE OF INTENT – SOLE-SOURCE ACQUISITION
Notice No.: 75N98027Q00020
The National Institutes of Health (NIH), National Cancer Ibstitute (NCI), intends to award a Firm-Fixed-Price Purchase Order to Plasmidsaurus Inc. for RNA sequencing and whole genome sequencing services for various wild-type, drug-treated cell lines
and samples related to CRISPR research.
Description of the Requirement
The primary objective of this study is to investigate common lymphoma-related translocations involving MYC, BCL6, or BCL2, while also examining copy number alterations and making CNV calls for genes of interest. To achieve this, RNA sequencing will be provided for samples generated in the Staudt laboratory. RNA sequencing is essential for characterizing genome edits and conducting transcriptomic analysis. By utilizing Plasmidsaurus, a faster and more scalable alternative to traditional sequencing methods based on the latest Oxford Nanopore Technologies platform, we aim to generate results that will deepen our understanding of cellular mechanisms involved in B-cell lymphoma and guide future downstream experiments. RNA sequencing and Whole-genome sequencing are required to observe the effects of various drugs on gene expression, identify pathways, and discover novel pathways.
Justification for the Proposed Sole-Source Acquisition
The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.
Plasmidsaurus uses the latest Oxford Nanopore Technologies platform, a faster, more scalable alternative to traditional sequencing. Using the latest Oxford Nanopore Technologies platform ensures accurate sequencing, which is crucial for reproducible experiments which will significantly advance our understanding of, and treatment for, B-cell lymphoma, which is vital to cancer research at the National Cancer Institute.
Response Information
This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements.
The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate.
The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement.
Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 6, 2026.
Please reference Notice No. 75N98027Q00043 in the subject line of the submission.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| NOI - DNA Sequencing of Bone Marrow Failure Syndro | Office of Logisitics and Acquisition Operations | No set-aside | |
| NOI - 4D-Nucleofector Core Unit and X Unit | Office of Logisitics and Acquisition Operations | No set-aside | |
| Amplicon sequencing services | Office of Acquisitions and Grants | No set-aside | |
| 1-Year OEM Service Contract - (2) Revvity Celigo S Imaging Instruments (VRC) | National Institute of Allergy and Infectious Diseases | No set-aside | |
| Clinical Research Support and Collaboration for NHGRI Protocols | Office of Logisitics and Acquisition Operations | Total Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity